环磷酰胺联合激素与他克莫司联合激素治疗原发性膜性肾病的长期随访对比
本研究对70例抵抗肾素-血管紧张素系统阻断剂的原发性膜性肾病患者进行6年随访,随机接受改良Ponticelli方案或他克莫司联合激素治疗。6年末,改良Ponticelli组无复发生存率显著高于他克莫司组(61.76% vs 28.12%,RR 2.19),总缓解率也更高(88.23% vs 53.12%,RR 1.66)。两组eGFR下降40%、死亡或终末期肾病比例无显著差异。
要点
- 改良Ponticelli方案长期无复发生存优于他克莫司联合激素。
- 改良Ponticelli组总缓解率显著更高。
- 两组肾脏硬终点事件无显著差异。
核心结论
- 长期来看,改良Ponticelli方案作为抗蛋白尿抵抗性原发性膜性肾病的一线治疗优于他克莫司联合激素。
研究设计与样本
- 前瞻性随机对照研究,70例患者1:1随机接受改良Ponticelli方案或他克莫司联合激素治疗,随访6年。
主要发现
- 6年末,改良Ponticelli组和他克莫司组分别有21例(61.76%)和9例(28.12%)维持无复发生存(RR 2.19,95%CI 1.23-4.15)。
- 6年末,改良Ponticelli组和他克莫司组分别有30例(88.23%)和17例(53.12%)处于缓解状态(包括复发)(RR 1.66,95%CI 1.21-2.45)。
- 两组在eGFR下降40%、死亡或终末期肾病比例上无显著差异。
- 改良Ponticelli组无实体器官或血液系统恶性肿瘤报告。
临床怎么用
- 对于抗蛋白尿治疗抵抗的原发性膜性肾病患者,可优先考虑改良Ponticelli方案作为一线治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Kidney Disease: Improving Global Outcomes (KDIGO) 2012 recommends cyclical cyclophosphamide plus glucocorticoids (GC) (modified Ponticelli regimen) or calcineurin inhibitors (CNIs) such as tacrolimus (TAC) or cyclosporine as the first-line agents for the management of primary membranous nephropathy (PMN) that is resistant to antiproteinuric therapy with renin-angiotensin system blockers. However, the long-term outcome of patients treated with CNIs is not known. METHODS: We report the outcomes of 70 patients randomized 1:1 to receive modified Ponticelli regimen or TAC/GC for renin-angiotensin system-resistant PMN who were prospectively followed for 6 years. Patients were followed monthly for 12 months, then quarterly for 12 months, and then every 6 months through the end of 6 years. RESULTS: At the end of 6 years, 21 (61.76%) and 9 (28.12%) patients maintained relapse-free remission in modified Ponticelli regimen and TAC/GC groups, respectively (relative risk [RR]: 2.19, 95% confidence interval [CI]: 1.23 to 4.15), and 30 (88.23%) and 17 (53.12%) patients were in remission (including relapses) in modified Ponticelli regimen and TAC/GC groups (RR: 1.66; 95% CI: 1.21 to 2.45), respectively. There was no significant difference in the proportion of patients who had a 40% decline in the estimated glomerular filtration rate (eGFR), death, or end-stage kidney disease between the groups. None of the patients treated with modified Ponticelli regimen reported a solid organ or hematological malignancy. CONCLUSIONS: To conclude, in the long-term, modified Ponticelli regimen is superior to TAC/GC as first-line therapy for the management of antiproteinuric-resistant PMN.
引用
- Ramachandran R, Kumar V, Bharati J, et al. Long-Term Follow-Up of Cyclical Cyclophosphamide and Steroids Versus Tacrolimus and Steroids in Primary Membranous Nephropathy. Kidney Int Rep. 2021. PMID: 34622104. doi:10.1016/j.ekir.2021.07.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。